Core Insights - Halozyme Therapeutics (HALO) reported a fourth-quarter 2025 adjusted loss of 24 cents per share, significantly below the Zacks Consensus Estimate of earnings of $2.15, and down from adjusted earnings of $1.26 per share in the same quarter last year [1][6] - The decline in earnings was primarily attributed to a $2.42 per share unfavorable impact from acquired IPR&D expenses related to the Surf Bio acquisition [1] Revenue Performance - Total revenues for the fourth quarter increased by 52% year over year to $451.8 million, surpassing the Zacks Consensus Estimate of $449 million [2] - The growth in revenue was driven by increased product sales and higher royalty payments, with royalty revenues totaling $258 million, up 51% from the previous year [4][6] Product Sales and Royalties - Product sales reached $122.7 million in the fourth quarter, reflecting a 54.5% increase year over year, although it fell short of the model estimate of $123.2 million [7] - Revenues under collaborative agreements were $71.1 million, marking a 47.5% year-over-year increase [7] Financial Metrics - Adjusted EBITDA for the quarter was $21.9 million, a significant decrease from $195.8 million in the same quarter last year [8] - As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $145.4 million, down from $702 million as of September 30, 2025 [8] Full-Year Results and Guidance - For the full year 2025, Halozyme generated revenues of $1.39 billion, a 38% increase year over year, with adjusted earnings of $4.15 per share, down from $4.23 per share in the previous year [9] - The company expects total revenues for 2026 to be between $1.71 billion and $1.81 billion, indicating year-over-year growth of 22% to 30% [10] - Royalty revenues for 2026 are anticipated to be in the range of $1.13 billion to $1.17 billion, reflecting a year-over-year growth of 30% to 35% [10] Future Expectations - Adjusted EBITDA for 2026 is projected to be between $1.125 billion and $1.205 billion, representing a year-over-year increase of 71% to 83% [11] - Adjusted earnings per share for 2026 are expected to be in the range of $7.75 to $8.25, indicating growth of 87% to 99% year over year [11] - Management anticipates a 5% to 10% decrease in royalty revenues for the first quarter of 2026 compared to the fourth quarter of 2025 due to annual contract rate adjustments [12]

Broader AI-linked and megacap technology stocks had lost ground earlier this month as investors demanded stronger evidence the heavy investments in the technology were tangibly boosting revenue and profits.Most megacap and growth stocks rose on the day, with Nvidia gaining 2.6 per cent after ​the company said it had signed a multi-year deal to sell Meta Platforms ⁠millions of ‌its current and future AI chips.Moderna jumped 7.7 percent after announcing that the US Food and Drug Administration would review i ...

Core Insights - The European Commission has granted ImmunityBio authorization for its bladder cancer treatment ANKTIVA, allowing the company to expand its commercial presence across four regulatory jurisdictions in under two years since its initial FDA approval [1][2] - ImmunityBio's stock has experienced a significant increase of 123.73% over the past year, currently trading at $7.46, which is 18.6% above its 20-day simple moving average (SMA) and 159.3% above its 200-day SMA [3] - Analysts have a positive outlook on ImmunityBio, with a consensus Buy rating and an average price target of $11.80, reflecting strong earnings expectations and recent upward revisions in revenue estimates [6] Regulatory and Market Expansion - The authorization includes key markets such as the Kingdom of Saudi Arabia, where ANKTIVA has received approval for two indications, indicating its growing acceptance and potential market impact [1] - ImmunityBio is committed to long-term safety and efficacy follow-ups with trial participants, which is essential for maintaining authorization and possibly expanding indications [2] Stock Performance and Analyst Sentiment - The stock's recent performance shows a robust upward trend, supported by solid fundamentals, despite mixed technical indicators suggesting some bearish pressure [3][4] - Upcoming earnings report is anticipated on March 2, 2026, with analysts finalizing forecasts, indicating heightened investor interest [5] - Recent analyst actions include maintaining a Buy rating and adjusting price targets, with D. Boral Capital maintaining a target of $24.00 and HC Wainwright & Co. raising their target to $10.00 [6]

Core Insights - Tempus AI (TEM) shares increased following the launch of a new AI algorithm for identifying cancer patients responsive to platinum-based chemotherapy, with preliminary Q4 revenue reported at $367 million, an 83% year-over-year increase, and total contract value exceeding $1.1 billion [1] Group 1: Company Developments - Tempus AI introduced the Pan-Cancer HRD-RNA algorithm, which utilizes RNA analysis to identify Homologous Recombination Deficiency, offering a real-time view of tumor biology [1] - The algorithm has shown that patients with HRD-RNA positive metastatic pancreatic cancer have significantly lower mortality risk compared to those receiving non-platinum therapies [1] - The algorithm is currently available for research purposes, with clinical availability anticipated later in 2026 [1] Group 2: Financial Performance - Preliminary Q4 revenue for Tempus was reported at $367 million, marking an 83% increase year-over-year [1] - The total contract value for Tempus exceeded $1.1 billion, indicating strong demand for its services [1] Group 3: Market Sentiment - Analysts have set a consensus target price of $85.69 for Tempus, suggesting nearly 50% upside from current trading levels [1] - The stock has received 2 Strong Buy and 5 Buy ratings, reflecting confidence in Tempus's revenue growth and expanding AI-driven diagnostics platform [1] - Despite recent volatility, the stock remains down 18.54% over the past month, indicating potential market concerns ahead of the earnings report [1]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Viewpoint - The FDA has agreed to review Moderna's experimental mRNA flu shot, reversing its earlier decision, which has surprised both Wall Street and the medical community [1][2]. Group 1: FDA Review and Approval Process - The FDA is expected to make a decision on the flu shot by August 5, which is crucial for Moderna's plans to introduce the vaccine for the upcoming influenza season [2]. - Moderna aims for full approval of the flu shot for adults aged 50 to 64 and accelerated approval for those aged 65 and older, which will require a post-marketing study to confirm benefits [5]. - The FDA's acceptance of the modified application follows a "constructive" meeting where Moderna proposed a revised regulatory approach addressing previous criticisms [4][5]. Group 2: Clinical Trial and Regulatory Concerns - The FDA had previously criticized Moderna's choice of comparator in its phase three trial, stating it did not reflect the best standard of care in the U.S. [6]. - Moderna contends that FDA guidelines do not mandate the use of the highest-dose vaccine as a comparator and argues that the agency's prior communications supported their trial design [8]. - The decision to initially refuse the application was influenced by the FDA's top vaccine regulator, who has advocated for stricter vaccine regulations [9][10]. Group 3: Market Reaction and Company Outlook - Following the announcement of the FDA's review, shares of Moderna increased by over 6% [3]. - The successful introduction of the flu vaccine is integral to Moderna's goal of achieving financial break-even by 2028 [2].

Core Insights - Tempus AI has introduced its new HRD-RNA algorithm, an AI-driven tool aimed at enhancing the detection of homologous recombination deficiency (HRD) in tumors, which has positively impacted its stock price [1][6] Product Development - The HRD-RNA algorithm analyzes gene expression to identify patients who may benefit from platinum-based chemotherapy or PARP inhibitors, providing a more dynamic assessment of tumor biology compared to traditional genomic methods [2] - A real-world validation study indicated that HRD-RNA–positive metastatic pancreatic cancer patients treated with first-line platinum-based regimens experienced a significant reduction in mortality risk compared to those receiving non-platinum therapies [2] - The company plans to make the HRD-RNA test clinically available later this year, offering physicians a functional view of HRD status by examining the transcriptome [3] Technical Analysis - The stock is currently trading 8.3% below its 20-day simple moving average (SMA) and 25.8% below its 100-day SMA, indicating a bearish trend [4] - Over the past 12 months, shares have decreased by 35.86%, positioning them closer to their 52-week lows [4] - The RSI is at 35.53, indicating neutral territory, while the MACD shows a value of -3.9401, below its signal line, suggesting bearish pressure [4][5] Analyst Outlook - Tempus AI is set to report earnings on February 24, 2026, with an EPS estimate of a loss of 13 cents, improved from a loss of 18 cents year-over-year [7][10] - Revenue estimates stand at $364.25 million, up from $200.68 million year-over-year [10] - The stock carries a Buy Rating with an average price target of $76.60, although recent analyst actions indicate mixed sentiments with some lowering their targets [8][10] Market Position - The company is positioned as a leader in precision medicine, leveraging AI to enhance treatment options and potentially improve patient outcomes [6] - Key resistance for the stock is identified at $61.50, while key support is at $50.00 [9] - Tempus AI shares were up 3.41% at $54.35 during premarket trading, reflecting some positive market activity [11]

Core Viewpoint - Heron Therapeutics (HRTX) has experienced a decline of over 10% year-to-date, despite an initial rally triggered by preliminary Q4'25 numbers earlier in January [1] Group 1: Company Performance - The company was previously rated a hold, with the analyst noting that HRTX had performed well in its operations [1] Group 2: Market Context - The focus of the analysis includes trading around significant events such as trial results and NDA/BLA approvals, indicating a strategic approach to biotech stock trading [1]

Moderna's stock was surging after the FDA said it would review the biotech's flu-vaccine candidate, a week after it had refused to do so. ...

Core Insights - Wall Street analysts expect Myriad Genetics (MYGN) to report a quarterly loss of -$0.02 per share, reflecting a year-over-year decline of 166.7% [1] - Revenues are projected to be $207.59 million, which is a decrease of 1.4% compared to the same quarter last year [1] - There have been no revisions in the consensus EPS estimate over the last 30 days, indicating stability in analysts' forecasts [1] Revenue Estimates - The consensus estimate for 'Revenue by core product - Prenatal' is $47.02 million, representing a year-over-year increase of 4.7% [3] - 'Revenue by core product - Hereditary Cancer' is expected to reach $94.87 million, suggesting a slight increase of 0.6% year over year [4] - 'Revenue by core product - Pharmacogenomics' is forecasted at $36.87 million, indicating a decline of 9.2% from the prior-year quarter [4] - 'Revenue by core product - Tumor Profiling' is estimated to be $28.59 million, reflecting a decrease of 7.2% year over year [4] Stock Performance - Over the past month, shares of Myriad have declined by 20.8%, while the Zacks S&P 500 composite has only decreased by 1.3% [5] - MYGN currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance in the near future [5]